Background: Neurological immune-related adverse events (nirAEs) are rare toxicities of immune-checkpoint inhibitors (ICI). With the increase of ICI oncological indications, their incidence is growing. Their recognition and management remain nevertheless challenging. Methods: A national, web-based database was built to collect cases of neurological symptoms in patients receiving ICI and not attributable to other causes after an adequate workup. Results: We identified 27 patients who developed nirAEs (20 males, median age 69 years). Patients received anti-PD1/PDL1 (78%), anti-CTLA4 (4%), or both (19%). Most common cancers were melanoma (30%) and non-small cell lung cancer (26%). Peripheral nervous system was mostly affected (78%). Median time to onset was 43.5 days and was shorter for peripheral versus central nervous system toxicities (36 versus 144.5 days, p = 0.045). Common manifestations were myositis (33%), inflammatory polyradiculoneuropathies (33%), and myasthenia gravis (19%), alone or in combination, but the spectrum of diagnoses was broad. Most patients received first-line glucocorticoids (85%) or IVIg (15%). Seven patients (26%) needed second-line treatments. At last follow-up, four (15%) patients were deceased (encephalitis, 1; myositis/myasthenia with concomitant myocarditis, 2; acute polyradiculoneuropathy, 1), while seven (26%) had a complete remission, eight (30%) partial improvement, and six (22%) stable/progressing symptoms. ICI treatment was discontinued in most patients (78%). Conclusions: Neurological irAEs are rare but potentially fatal. They primarily affect neuromuscular structures but encompass a broad range of presentations. A prompt recognition is mandatory to timely withheld immunotherapy and administrate glucocorticoids. In corticoresistant or severely affected patients, second-line treatments with IVIg or plasmapheresis may result in additional benefit.

Characterization and management of neurological adverse events during immune-checkpoint inhibitors treatment: an Italian multicentric experience

Bruno F.;Giometto B.;
2022-01-01

Abstract

Background: Neurological immune-related adverse events (nirAEs) are rare toxicities of immune-checkpoint inhibitors (ICI). With the increase of ICI oncological indications, their incidence is growing. Their recognition and management remain nevertheless challenging. Methods: A national, web-based database was built to collect cases of neurological symptoms in patients receiving ICI and not attributable to other causes after an adequate workup. Results: We identified 27 patients who developed nirAEs (20 males, median age 69 years). Patients received anti-PD1/PDL1 (78%), anti-CTLA4 (4%), or both (19%). Most common cancers were melanoma (30%) and non-small cell lung cancer (26%). Peripheral nervous system was mostly affected (78%). Median time to onset was 43.5 days and was shorter for peripheral versus central nervous system toxicities (36 versus 144.5 days, p = 0.045). Common manifestations were myositis (33%), inflammatory polyradiculoneuropathies (33%), and myasthenia gravis (19%), alone or in combination, but the spectrum of diagnoses was broad. Most patients received first-line glucocorticoids (85%) or IVIg (15%). Seven patients (26%) needed second-line treatments. At last follow-up, four (15%) patients were deceased (encephalitis, 1; myositis/myasthenia with concomitant myocarditis, 2; acute polyradiculoneuropathy, 1), while seven (26%) had a complete remission, eight (30%) partial improvement, and six (22%) stable/progressing symptoms. ICI treatment was discontinued in most patients (78%). Conclusions: Neurological irAEs are rare but potentially fatal. They primarily affect neuromuscular structures but encompass a broad range of presentations. A prompt recognition is mandatory to timely withheld immunotherapy and administrate glucocorticoids. In corticoresistant or severely affected patients, second-line treatments with IVIg or plasmapheresis may result in additional benefit.
2022
23-ago-2021
Pubblicato
File in questo prodotto:
File Dimensione Formato  
Diamanti2022_Article_CharacterizationAndManagementO.pdf

Accesso chiuso

Tipologia: Documento in Versione Editoriale
Licenza: Copyright Editore
Dimensione 2.36 MB
Formato Adobe PDF
2.36 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
10072_2021_5561_MOESM1_ESM.pdf

Accesso chiuso

Descrizione: Supplementary file 1
Tipologia: Altro materiale allegato
Licenza: Digital Rights Management non definito
Dimensione 220.06 kB
Formato Adobe PDF
220.06 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
10072_2021_5561_MOESM2_ESM.pdf

Accesso chiuso

Descrizione: Supplementary file 2
Tipologia: Altro materiale allegato
Licenza: Digital Rights Management non definito
Dimensione 494 kB
Formato Adobe PDF
494 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
10072_2021_5561_MOESM3_ESM.pdf

Accesso chiuso

Descrizione: Supplementary file 3
Tipologia: Altro materiale allegato
Licenza: Digital Rights Management non definito
Dimensione 457.15 kB
Formato Adobe PDF
457.15 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
10072_2021_5561_MOESM4_ESM.pdf

Accesso chiuso

Descrizione: Supplementary file 4
Tipologia: Altro materiale allegato
Licenza: Digital Rights Management non definito
Dimensione 415.47 kB
Formato Adobe PDF
415.47 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
3021265_Diamanti2022_Article_CharacterizationAndManagementO-Post_print.pdf

Open Access dal 24/08/2022

Tipologia: Bozza finale post-referaggio (post-print)
Licenza: Digital Rights Management non definito
Dimensione 2.87 MB
Formato Adobe PDF
2.87 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11368/3021265
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 16
  • ???jsp.display-item.citation.isi??? 13
social impact